Selexis SA, a JSR Life Sciences company, and NexImmune Inc., a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies, have signed a service agreement to develop cell lines targeting rare cancers and autoimmune diseases and to advance two HLAs that can be used to expand treatments to more patients.   Per the agreement, NexImmune will leverage Selexis’ SUREtechnology Platform, a suite of cell line development technologies that significantly reduce the time, ...